Tandem Diabetes Care Inc. (TNDM) vs its competitors

Tandem Diabetes Care Inc. against medical devices

Tandem Diabetes Care Inc. is the 34th largest of 132 graded companies. Showing 5 of them, including TNDM itself. 11 more are in this industry but have no grade yet, so they are left out rather than shown blank.

Company	Grade	Market value	Revenue	Profit margin	Free cash flow	Price to earnings
Abbott LaboratoriesABT	B+	$175.9B	$45.1B	13.9%	$7.4B	28.20
Medtronic plcMDT	A+	$111.4B	$37.5B	13.9%	$6.1B	21.40
Stryker Corp.SYK	A+	$107B	$25.8B	14.4%	$4.7B	28.90
Boston Scientific CorporationBSX	B+	$63.6B	$21B	17.5%	$3.6B	17.77
Tandem Diabetes Care, Inc.TNDM	B-	$1.2B	$1B	-6.1%	-$26.6M	—

127 more medical devices companies

Graded on the same five checks, from their own SEC filings.

A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.

Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Tandem Diabetes Care Inc. on the overview — nothing here comes from a data vendor’s own ratios.

Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.